title: Successful treatment of extramedullary plasmacytoma of the cavernous sinus using a combination of intermediate dose of thalidomide and dexamethasone.
authors.affiliation: Department of Haematology, Papageorgiou General Hospital, Thessaloniki, Greece.
authors.forename: Eirini
authors.initials: E
authors.lastname: Katodritou
authors.forename: Matthaios
authors.initials: M
authors.lastname: Speletas
authors.forename: Anastasia
authors.initials: A
authors.lastname: Pouli
authors.forename: John
authors.initials: J
authors.lastname: Tsitouridis
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Zervas
authors.forename: Evangelos
authors.initials: E
authors.lastname: Terpos
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002426:Cavernous Sinus / Q000473:pathology*; D003907:Dexamethasone / Q000008:administration & dosage; D004172:Diplopia / Q000209:etiology; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D009383:Neoplasms, Vascular Tissue / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D010954:Plasmacytoma / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D012074:Remission Induction; D013792:Thalidomide / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D020533:Angiogenesis Inhibitors; D013792:Thalidomide; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin